Vega Health Submits Comments to FDA on Considerations for Regulation of GenAI-Enabled Medical Devices

Vega Health submitted comments to the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) on its Considerations for the Regulation of Generative AI-Enabled Medical Devices (referred to throughout as “GenAI-Enabled Devices” for consistency with FDA discussion paper language). We commend CDRH for engaging stakeholders early and for recognizing that the unique characteristics of GenAI-enabled devices may require evaluation and oversight approaches distinct from those developed for traditional software-based medical devices.

In our comments, Vega Health encourages CDRH to consider the following:

• Ensure that selected premarket evaluation and post market monitoring
  approaches are flexible, relevant to patients and providers, meaningful in real-world deployment contexts, and implementable in Artificial Intelligence/Super Intelligence (hereafter, “SI”) product lifecycle management;
• Anchor frameworks on the categories of evidence and methodological rigor necessary to inform regulatory decision-making, not the specific technology;
• Adopt a total product lifecycle approach to regulatory approval of GenAI-enabled devices;
• Include local evaluation as a pathway to satisfy clinical confirmation evaluations to support the development of essential health system infrastructure; and
• Build on the success of the Sentinel Initiative to advance the use of GenAI- enabled devices for healthcare performance improvement.

Vega Health appreciates the opportunity to provide comments to the FDA CDRH on the considerations outlined in this discussion paper.